CY1123028T1 - Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf - Google Patents

Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf

Info

Publication number
CY1123028T1
CY1123028T1 CY20201100507T CY201100507T CY1123028T1 CY 1123028 T1 CY1123028 T1 CY 1123028T1 CY 20201100507 T CY20201100507 T CY 20201100507T CY 201100507 T CY201100507 T CY 201100507T CY 1123028 T1 CY1123028 T1 CY 1123028T1
Authority
CY
Cyprus
Prior art keywords
antibodies
fixed
vegf
soluble vegf
inhibiting antibodies
Prior art date
Application number
CY20201100507T
Other languages
English (en)
Inventor
Leonardo Borras
David Urech
Tea Gunde
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1123028T1 publication Critical patent/CY1123028T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε διαλυτούς και σταθερούς ανοσοσυνδέτες αντι-VEGF που αποτελούνται από CDRs από μονοκλωνικά αντισώματα κoυνελιού. Τα εν λόγω αντισώματα είναι σχεδιασμένα για τη διάγνωση ή/και θεραπευτική αγωγή διαμεσολαβούμενων από τον VEGF διαταραχών. Τα υβριδώματα, νουκλεϊνικά οξέα, φορείς και κύτταρα ξενιστές για την έκφραση των ανασυνδυασμένων αντισωμάτων της εφεύρεσης, μέθοδοι για την απομόνωση τους και η χρήση των εν λόγω αντισωμάτων στην ιατρική αποκαλύπτονται επίσης.
CY20201100507T 2008-06-25 2020-06-05 Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf CY1123028T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7569208P 2008-06-25 2008-06-25
US7569708P 2008-06-25 2008-06-25
US13321208P 2008-06-25 2008-06-25
US15504109P 2009-02-24 2009-02-24
PCT/CH2009/000220 WO2009155724A2 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting vegf
EP09768693.5A EP2307454B1 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting vegf

Publications (1)

Publication Number Publication Date
CY1123028T1 true CY1123028T1 (el) 2021-10-29

Family

ID=41209803

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20171100436T CY1118829T1 (el) 2008-06-25 2017-04-12 Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων
CY20201100507T CY1123028T1 (el) 2008-06-25 2020-06-05 Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
CY2020026C CY2020026I1 (el) 2008-06-25 2020-07-30 Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20171100436T CY1118829T1 (el) 2008-06-25 2017-04-12 Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2020026C CY2020026I1 (el) 2008-06-25 2020-07-30 Ανασταλτικος vegf σταθερων και διαλυτων αντισωματων

Country Status (26)

Country Link
US (5) US8349322B2 (el)
EP (3) EP2307454B1 (el)
JP (7) JP5956752B2 (el)
KR (8) KR101817284B1 (el)
CN (3) CN102143976B (el)
AU (1) AU2009264565C1 (el)
BR (1) BRPI0914251B1 (el)
CA (2) CA3020290A1 (el)
CL (1) CL2010001544A1 (el)
CY (3) CY1118829T1 (el)
DK (2) DK3216803T3 (el)
ES (2) ES2622470T3 (el)
HK (1) HK1150844A1 (el)
HR (2) HRP20170615T1 (el)
HU (3) HUE032894T2 (el)
LT (3) LT3216803T (el)
MX (2) MX2011000011A (el)
NL (1) NL301058I2 (el)
NO (1) NO2020021I1 (el)
PH (1) PH12015501593A1 (el)
PL (2) PL2307454T3 (el)
PT (2) PT3216803T (el)
RU (6) RU2588467C3 (el)
SI (2) SI3216803T1 (el)
WO (1) WO2009155724A2 (el)
ZA (1) ZA201008594B (el)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110122881A (ko) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
BRPI0914319B8 (pt) 2008-06-25 2021-05-25 Esbatech Alcon Biomed Res Unit imunoligante que se liga especificamente ao tnf alfa humano e composição
CA3020290A1 (en) 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
MX344076B (es) 2008-06-30 2016-12-05 Esbatech Alcon Biomed Res Unit Polipeptidos funcionalizados.
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JP5764071B2 (ja) 2009-02-24 2015-08-12 エスバテック − ア ノバルティスカンパニー エルエルシー 細胞表面抗原のイムノバインダーを同定するための方法
BRPI1011940B8 (pt) 2009-06-22 2021-08-03 Amgen Inc método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
EP2445924B2 (en) 2009-06-25 2023-12-13 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
US20130280167A1 (en) * 2010-10-19 2013-10-24 Moses Rodriguez Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
ES2604837T3 (es) 2012-02-02 2017-03-09 Esbatech - A Novartis Company Llc Formulación de liberación sostenida que contiene anticuerpos para administración ocular
EP3495387B1 (en) 2012-07-13 2021-09-01 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
CA2891686A1 (en) 2012-12-18 2014-06-26 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
EP3693381A1 (en) 2013-02-18 2020-08-12 Vegenics Pty Limited Ligand binding molecules and uses thereof
KR101541478B1 (ko) * 2013-05-31 2015-08-05 동아쏘시오홀딩스 주식회사 항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
WO2014206561A1 (en) 2013-06-26 2014-12-31 Numab Ag Novel antibody frameworks
CN110193009A (zh) 2013-07-12 2019-09-03 伊维希比奥公司 用于治疗或预防眼科病的方法
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
WO2015173260A1 (en) 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
EP3160990A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
KR102390359B1 (ko) 2014-09-29 2022-04-22 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI806150B (zh) * 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
RU2699544C2 (ru) 2015-01-28 2019-09-06 Пфайзер Инк. Стабильная водная композиция антитела против фактора роста эндотелия сосудов (VEGF)
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
US10851399B2 (en) * 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
MA43113B1 (fr) 2015-10-30 2021-06-30 Hoffmann La Roche Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EP3375875A4 (en) * 2015-11-09 2018-12-05 National University Corporation Kyoto Institute of Technology SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
CN108883057A (zh) 2015-11-18 2018-11-23 Sio2医药产品公司 用于眼科配制品的药物包装
RU2734958C2 (ru) 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN108779172B (zh) 2016-01-06 2022-02-08 定制药品研究株式会社 抑制vegf与nrp1结合的抗体
US11007259B2 (en) 2016-01-06 2021-05-18 Order-Made Medical Research Inc. High-affinity anti-VEGF antibody
USD789171S1 (en) 2016-01-21 2017-06-13 Nomis Llc Right angle drive
CA3011638C (en) 2016-01-26 2023-01-10 Formycon Ag Liquid formulation of a vegf antagonist
WO2017136807A1 (en) * 2016-02-05 2017-08-10 The Board Of Regents Of The University Of Texas System Egfl6 specific monoclonal antibodies and methods of their use
WO2017156423A2 (en) * 2016-03-11 2017-09-14 Integrated Biotherapeutics, Inc. Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) * 2016-03-23 2017-09-27 LANXESS Deutschland GmbH Metallazopigmente
WO2017181031A2 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
FI3479819T3 (fi) 2016-06-30 2024-04-17 Celltrion Inc Stabiili nestemäinen farmaseuttinen valmiste
WO2018009939A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
CA3055256A1 (en) * 2017-03-09 2018-09-13 Mab Discovery Gmbh Antibodies specifically binding to human il-1r7
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN110636859B (zh) 2017-05-19 2024-05-03 科学与工业研究委员会 用于产生重折叠的重组人源化兰尼单抗的方法
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
EP3630043A1 (en) 2017-05-24 2020-04-08 Formycon AG Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
CA3063995A1 (en) 2017-05-24 2018-11-29 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
JP7474193B2 (ja) * 2017-06-25 2024-04-24 システィミューン， インク． 多重特異性抗体とその作製及び使用方法
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
AU2018372235B9 (en) * 2017-11-27 2022-03-10 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN111511400A (zh) 2017-12-29 2020-08-07 豪夫迈·罗氏有限公司 抗vegf抗体及其使用方法
WO2019143837A1 (en) * 2018-01-17 2019-07-25 Apexigen, Inc. Anti-pd-l1 antibodies and methods of use
EP3765083A1 (en) 2018-03-16 2021-01-20 Novartis Ag Methods for treating ocular diseases
US20210163605A1 (en) * 2018-04-06 2021-06-03 Eli Lilly And Company Ramucirumab for the treatment of cancers in pediatric patients
AU2019328575A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
KR20210069639A (ko) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. 단일-사슬 키메라 폴리펩타이드 및 이의 용도
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
JOP20210152A1 (ar) 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
USD907455S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drive attachment
USD907456S1 (en) 2019-05-21 2021-01-12 Nomis Llc Right angle drill attachment
JP2022537054A (ja) 2019-06-21 2022-08-23 エイチシーダブリュー バイオロジックス インコーポレイテッド 多鎖キメラポリペプチドおよびその使用
US20240052024A1 (en) 2019-09-13 2024-02-15 Novartis Ag Methods for treating ocular diseases
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115362169A (zh) 2020-02-11 2022-11-18 Hcw生物科技公司 色谱树脂以及其用途
EP4103599A1 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of activating regulatory t cells
EP4103601A2 (en) 2020-02-11 2022-12-21 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
WO2021174127A1 (en) * 2020-02-28 2021-09-02 Apexigen, Inc. Anti-sirpa antibodies and methods of use
BR112022018088A2 (pt) * 2020-03-12 2023-01-17 Immune Onc Therapeutics Inc Novos anticorpos anti-lilrb4 e produtos derivados
WO2021183849A1 (en) 2020-03-13 2021-09-16 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
AU2021262794A1 (en) 2020-04-29 2022-11-24 HCW Biologics, Inc. Anti-CD26 proteins and uses thereof
JP2023527869A (ja) 2020-06-01 2023-06-30 エイチシーダブリュー バイオロジックス インコーポレイテッド 加齢関連障害の治療法
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
AU2021308712A1 (en) 2020-07-16 2023-02-02 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
IL302089A (en) 2020-10-15 2023-06-01 Hoffmann La Roche Non-covalent protein-hyaluronan conjugates for long-term ocular delivery
TW202237181A (zh) 2020-11-25 2022-10-01 瑞士商諾華公司 治療眼部疾病之方法
WO2022201084A1 (en) 2021-03-26 2022-09-29 Novartis Ag Methods for treating ocular diseases
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
KR20230094450A (ko) 2021-12-21 2023-06-28 한림대학교 산학협력단 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
WO2023168363A1 (en) 2022-03-02 2023-09-07 HCW Biologics, Inc. Method of treating pancreatic cancer
TW202337496A (zh) 2022-03-17 2023-10-01 瑞士商諾華公司 治療新生血管性年齡相關性黃斑點退化之方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
OA10149A (en) 1991-03-29 1996-12-18 Genentech Inc Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
DE69233803D1 (de) 1992-10-28 2011-03-31 Genentech Inc Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
ATE253593T1 (de) * 1996-07-16 2003-11-15 Plueckthun Andreas Prof Dr Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO2000053760A2 (en) 1999-03-12 2000-09-14 Genentech, Inc. Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
EP0971959B1 (en) * 1997-04-07 2005-12-28 Genentech, Inc. Humanized antibodies and methods for forming humanized antibodies
AU743758B2 (en) * 1997-04-07 2002-02-07 Genentech Inc. Anti-VEGF antibodies
WO2000034337A1 (en) 1998-12-10 2000-06-15 Tsukuba Research Laboratory, Toagosei Co., Ltd. Humanized monoclonal antibodies against vascular endothelial cell growth factor
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
JP4926320B2 (ja) 1999-04-28 2012-05-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Ｖｅｇｆの選択的阻害による癌処置のための組成物および方法
AU1102401A (en) * 1999-10-22 2001-05-08 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
CA2396534C (en) 1999-12-28 2012-10-02 Esbatech Ag Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de) 2002-01-16 2004-09-02 Infineon Technologies Ag Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en) 2002-02-20 2003-06-10 Samsung Electronics Co., Ltd. Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) * 2002-03-20 2005-02-02 上海中信国健药业有限公司 人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
NZ536412A (en) * 2002-05-22 2008-10-31 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
US20040086979A1 (en) * 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
NZ621449A (en) 2003-05-30 2015-07-31 Genentech Inc Treatment with anti-vegf antibodies
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
WO2005016950A1 (en) * 2003-08-07 2005-02-24 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
DK1781321T3 (da) 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
EP2319492A3 (en) 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
US7462697B2 (en) * 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
CA2619244A1 (en) * 2005-08-15 2007-02-22 Arana Therapeutics Limited Engineered antibodies with new world primate framework regions
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
AU2007272224B2 (en) 2006-07-10 2013-05-02 Novartis Ag scFv antibodies which pass epithelial and/or endothelial layers
WO2008063932A2 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
US7553486B2 (en) 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
ES2582656T3 (es) 2006-12-19 2016-09-14 Genentech, Inc. Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CA2688433A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN103435696B (zh) 2007-06-25 2016-10-12 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
EP2259795B1 (en) * 2008-03-26 2016-04-06 Epitomics, Inc. Anti-vegf antibody
JP5745720B2 (ja) 2008-06-25 2015-07-08 エスバテック − ア ノバルティスカンパニー エルエルシー イムノバインダーの溶解性の最適化
CA3020290A1 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
WO2010003268A2 (en) * 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
JP5914353B2 (ja) * 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法

Also Published As

Publication number Publication date
ES2622470T3 (es) 2017-07-06
MX347972B (es) 2017-05-22
JP6100199B2 (ja) 2017-03-22
RU2747735C3 (ru) 2022-05-04
RU2747735C2 (ru) 2021-05-13
EP2307454A2 (en) 2011-04-13
JP2017055774A (ja) 2017-03-23
EP2307454B1 (en) 2017-01-18
LTC2307454I2 (lt) 2021-05-25
PL2307454T3 (pl) 2017-07-31
CY2020026I2 (el) 2020-11-25
JP2022020782A (ja) 2022-02-01
ZA201008594B (en) 2012-02-29
JP2018108081A (ja) 2018-07-12
KR20180005753A (ko) 2018-01-16
JP2015134792A (ja) 2015-07-27
US10590193B2 (en) 2020-03-17
KR20150132602A (ko) 2015-11-25
DK2307454T3 (en) 2017-04-24
HRP20200814T1 (hr) 2020-08-07
AU2009264565A1 (en) 2009-12-30
CN104961828B (zh) 2019-03-26
AU2009264565B2 (en) 2014-05-08
US20200172608A1 (en) 2020-06-04
CN104961828A (zh) 2015-10-07
CA2727839C (en) 2018-11-20
US9090684B2 (en) 2015-07-28
US20180072802A1 (en) 2018-03-15
JP6527128B2 (ja) 2019-06-05
RU2016119152A (ru) 2017-11-21
CN102143976B (zh) 2015-11-25
WO2009155724A3 (en) 2010-04-01
WO2009155724A2 (en) 2009-12-30
RU2531523C2 (ru) 2014-10-20
LT2307454T (lt) 2017-05-25
US20140004114A1 (en) 2014-01-02
RU2648152C2 (ru) 2018-03-22
KR101671886B1 (ko) 2016-11-04
KR102013220B1 (ko) 2019-08-23
LT3216803T (lt) 2020-06-10
LTPA2020004I1 (lt) 2020-08-10
CA3020290A1 (en) 2009-12-30
CN110372792A (zh) 2019-10-25
EP3216803B1 (en) 2020-03-11
NL301058I2 (nl) 2020-10-27
SI2307454T1 (sl) 2017-05-31
BRPI0914251A2 (pt) 2021-01-05
US8349322B2 (en) 2013-01-08
CA2727839A1 (en) 2009-12-30
JP7171877B6 (ja) 2024-02-06
JP6978468B2 (ja) 2021-12-08
JP2014158491A (ja) 2014-09-04
KR20200108922A (ko) 2020-09-21
MX2011000011A (es) 2011-09-27
JP2019162127A (ja) 2019-09-26
BRPI0914251B1 (pt) 2022-07-19
RU2531523C9 (ru) 2015-04-10
KR20170057462A (ko) 2017-05-24
EP3722310A1 (en) 2020-10-14
CN102143976A (zh) 2011-08-03
SI3216803T1 (sl) 2020-07-31
RU2019120079A3 (el) 2020-12-28
PL3216803T3 (pl) 2020-10-19
RU2014132888A (ru) 2015-12-10
DK3216803T3 (da) 2020-06-02
KR20160128458A (ko) 2016-11-07
ES2793008T3 (es) 2020-11-12
RU2019120079A (ru) 2020-12-28
RU2531523C3 (ru) 2022-05-04
JP7171877B2 (ja) 2022-11-15
JP6821612B2 (ja) 2021-01-27
CL2010001544A1 (es) 2012-02-03
RU2588467C3 (ru) 2021-10-20
KR102095257B1 (ko) 2020-04-01
CY1118829T1 (el) 2018-01-10
JP2011525359A (ja) 2011-09-22
HUE050230T2 (hu) 2020-11-30
HK1150844A1 (zh) 2012-01-13
RU2013133802A (ru) 2015-01-27
PH12015501593A1 (en) 2015-12-14
KR20180098705A (ko) 2018-09-04
PT2307454T (pt) 2017-04-26
KR20190092630A (ko) 2019-08-07
US9873737B2 (en) 2018-01-23
HRP20170615T1 (hr) 2017-07-28
AU2009264565C1 (en) 2022-01-27
HUS2000028I1 (hu) 2020-08-28
US20150274820A1 (en) 2015-10-01
KR101737466B1 (ko) 2017-05-18
US20120014958A1 (en) 2012-01-19
RU2011102583A (ru) 2012-07-27
PT3216803T (pt) 2020-06-16
KR102296443B1 (ko) 2021-09-01
KR101817284B1 (ko) 2018-01-11
HUE032894T2 (hu) 2017-11-28
EP3216803A1 (en) 2017-09-13
JP5956752B2 (ja) 2016-07-27
KR20110028518A (ko) 2011-03-18
CY2020026I1 (el) 2020-11-25
NL301058I1 (el) 2020-07-31
RU2696972C1 (ru) 2019-08-07
KR102157097B1 (ko) 2020-09-18
NO2020021I1 (no) 2020-08-04

Similar Documents

Publication Publication Date Title
CY1123028T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν τον vegf
CY1124867T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1123435T1 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
CY1125429T1 (el) Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης
BR112019007281A2 (pt) proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1125102T1 (el) Αντιγονοδεσμευτικες πρωτεϊνες που ενεργοποιουν τον υποδοχεα λεπτινης
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
CY1118549T1 (el) Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου
CY1118693T1 (el) Αντισωματα αντι-ακτιβινης α και χρησεις αυτων
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
EA201000238A1 (ru) Антигенсвязывающие белки для il-18 рецептора и их применение
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)